Establishing a Clinical Transparency Committee is Key to Managing Global Disclosure

October 9, 2018

As seen on AppliedClinicalTrialsOnline.com - Posted Oct. 9, 2018 - Original Article

June 26, 2018 | By Thomas Wicks | A consistent and reliable approach to the increasing public availability of clinical trial data is dependent on a clear corporate policy and thoughtful coordination across the organization. To develop the necessary transparency policy and to ensure compliant and globally harmonized disclosure requires the active involvement from leaders across the organization collaborating through a cross-functional transparency committee.​


While it is common to think of clinical transparency in terms of disclosure regulations and trial registries, the truth is that clinical trial data is made available through many other outlets, including publications, corporate or health advocacy websites, and direct communications to patients or healthcare providers. The challenge is to coordinate the disclosure of data so that the publicly available information is globally consistent, timely, and accurate. 

Continued on Applied Clinical Trials

Previous Article
Executive Moves: KRS, TrialScope, NVA and HERMA US
Executive Moves: KRS, TrialScope, NVA and HERMA US

Next Article
Why sponsors need a global view of clinical trial compliance
Why sponsors need a global view of clinical trial compliance